PS 14-58 COMPARISON OF LISINOPRIL/AMLODIPINE AND TELMISARTAN/AMLODIPINE COMBINATIONS IN THE MANAGEMENT OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME

Objective: High blood pressure is considered one of the key features of metabolic syndrome. Aim of the study was to compare the efficacy and tolerability of lisinopril 2.5 mg + amlodipine 5 mg combination (L+A) versus telmisartan 20 mg + amlodipin 5 mg (T+A) combination in patients with MS. Design and Method: We investigated 72 hypertensive patients with metabolic syndrome with arterial hypertension not adequately controlled by a monotherapy with ACE inhibitors or calcium channel blockers or ARB entered this work, randomized, parallel-group study. After a two week placebo run-in, all patients with sitting diastolic blood pressure (DBP) > 95 mmHg and/or sitting systolic (BP > 160 mmHg were randomized to receive either L+A (36 patients) or T+A (36 patients) once daily for 12 weeks. Main outcome measure was sitting DBP and SBP values at the end of active treatment. The response rate was defined as the proportion of patients with either a final sitting DBP < 90 mmHg or decreased by at least 10 mmHg or a sitting SBP < 150 mmHg or decreased by at least 20 mmHg from baseline. Results: The DBP and SBP values obtained with T+A were, respectively, 2.1 and 2.8 mmHg lower than those obtained with L+A (both p < 0.005). The response rate in the T+A group (92.8%) was better than that observed in the L+A group (89.2%, p = 0.002). The incidence of adverse events was similar with the 2 treatment groups (15.4% vs. 17.5 %, p < 0.02). Conclusions: These data suggest a higher antihypertensive efficacy of the fixed combination T 20 mg + A 5 mg as compared with L 2.5 mg + A 5 mg. Further investigations are required with a large amount of patients.

Ҳали таржима қилинмаган